NCT03633747 is a Phase 1, PHASE2 clinical trial of Propranolol Hydrochloride in Hemangioma Liver, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT03633747?

NCT03633747 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT03633747?

Interventions in NCT03633747: Propranolol Hydrochloride.

What condition does NCT03633747 study?

NCT03633747 studies Hemangioma Liver.

Is NCT03633747 still recruiting?

NCT03633747 is currently terminated. Last updated 22 May 2025.

Last reviewed 2025-05-22 · How we verify

NCT03633747

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma

Terminated Phase 1, PHASE2 Last updated 22 May 2025

What this trial tests

Phase 1, PHASE2 trial testing Propranolol Hydrochloride in Hemangioma Liver in 8 participants. Terminated before completion.

Timeline

1 July 2018

Primary endpoint
31 August 2020

31 December 2021

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	1 July 2018
Primary completion	31 August 2020
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Propranolol Hydrochloride — full drug profile →

Conditions studied

Hemangioma Liver — all drugs for Hemangioma Liver →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 65, any sex, with Hemangioma Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatic hemangioma is one of the most common benign tumor of the liver. Although the overall prognosis is good, active interventions are still needed in high-risk patients. Without specific drugs, the main treatment methods include surgical treatments, interventional therapies and radiotherapies. Effective medical treatments are needed urgently. Propranolol has achieved good results in infantile Facial/hepatic hemangioma, and shows some effectiveness in adult hemangioma. Here, investigators intend to evaluate the therapeutic effect of propranolol in adult hepatic hemangioma.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.
Pu T, Sun J, Ren G, Li H. · · 2025 · cited 34× · PMID 40456735 · DOI 10.1038/s41392-025-02241-8
Drug Repurposing for Cancer Treatment: A Comprehensive Review.
Al Khzem AH, Gomaa MS, Alturki MS, Tawfeeq N, et al · · 2024 · cited 24× · PMID 39596504 · DOI 10.3390/ijms252212441
The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases.
Cuesta AM, Gallardo-Vara E, Casado-Vela J, Recio-Poveda L, et al · · 2022 · cited 18× · PMID 35457036 · DOI 10.3390/ijms23084217
PI3K signalling at the intersection of cardio-oncology networks: cardiac safety in the era of AI.
Ezeani M, Prabhu S. · · 2022 · PMID 36380172 · DOI 10.1007/s00018-022-04627-1

Verify or expand the search:

Other trials of Propranolol Hydrochloride

Trials testing the same drug.

NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
NCT06445166 — Propranolol for the Treatment of Kaposi Sarcoma in Adults · Phase 2 · recruiting
NCT05997732 — Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences · Phase 4 · recruiting
NCT05219799 — Sex Disparities in Hypoxic Vasodilation and Impact of Obesity · EARLY_PHASE1 · recruiting
NCT05651594 — Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanc · Phase 2 · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03633747 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 22 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03633747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing